Replies to post #237292 on Biotech Values

[WorstLuck]

Thanks for the comments.

Having now listened to the conference call the only thing that was reinforced in my mind is that the primary focus of the AdCom is likely to revolve around MACE. No shock at all there as it's more or less been the focus for quite some time. Yes, the transparency of the trial results and possibly design issues in NDD matter, as have been pointed out so many times before.

How much influence outside groups and individuals can have (given that it is an adcom and that it occasionally matters) might be interesting.